This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2025
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2025 | 990 | $267,774 | $512,994 | $208,000 | $877,106 | $443,390 |
| FY2024 | 990 | $266,071 | $503,704 | $310,296 | $1,295,871 | $688,610 |
| FY2023 | 990 | $552,239 | $463,359 | $230,000 | $1,550,183 | $926,243 |
| FY2022 | 990 | $285,427 | $538,950 | $327,257 | $1,330,627 | $837,363 |
| FY2021 | 990 | $530,327 | $235,519 | $24,964 | $1,468,414 | $1,090,886 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 56% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| Cornell UniversityNew Youk, NY | Isolation and molecular characterization of CNS-derived, cell-specific extracellular vesicles from Multiple Sclerosis blood Samples and Identify Clostridium perfringens Epsilon Toxin Specific Extracellular Vesicle Signature in MS Patients | $150,000 | 2024 |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Scott Johnson | CEO | 20 | $120,000 |
| Andy Cates | Director | 1 | $0 |
| Bobby Mehta | Director | 1 | $0 |
| Jim Gidwitz | Director |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| John Hopkins School of MedicineChicago, IL | MRF funds two projects at John Hopkins. One is to study oligodendrocyte extacellular vesicles as possible biomarkers of remyelination. The second is to study macrophage migration inhibitor factor(MIF) as a biomarker of neuronal and oligodendrocyte death and disease severity in MS | $135,610 | 2022 |
| Yale UniversityNew Haven, CT | There are two scientific research agreements with Yale for $50,000 each. The first is to validate the exosomal small RNA biomarker for MS progression in an additional validation cohort, consisting of 40 progressive and stable MS patients and then confirm the astrocyte origin of progression-associated RNAs by verifying their expression or downregulation in reactive astrocytes in autopsied brain tissue from progressive MS patients. Lastly, to test whether GLAST+ exosomes from progressive but not stable MS patients or healthy controls induce proinflammatory pathways in human iPSC-derived microglial cells that are also active in microglial populations in the brain of progressive MS patients. The second SRA aims to Develop a robust protocol to isolate OL-derived exosomes and quantify their lipid and protein content and determine the small RNA, lipid and proteomic signatures in oligodendrocyte-exosomes correlated to remyelination using samples from the RENEW optic neuritis treatment trial. | $100,000 | 2025 |
| John Hopkins School of MedicineChicago, IL | Chi separation of QSM images: A new tool to image myelin vs iron in chronic MS lesions | $50,296 | 2024 |
| Columbia UniversityNew York, NY | This study will test the diagnostic potential of extracellular vesicles (EVs) released by microglia. Microglia are resident immune cells in the central nervous system (CNS) which perform multiple functions including, immune response to local environment, communication with all CNS cells (neurons, astrocytes and oligodendrocytes) and phagocytic clearance of misfolded proteins and apoptotic or necrotic cells. EVs derived from microglia can play an important role as mediators of both pathological and reparative mechanisms in MS. Microglia are known to play key roles in both active inflammation and remyelination in MS | $50,000 | 2023 |
| Oregon Health & Science UniversityPortland, OR | MRF funds the addition of EVs to OHSU experiment that is using evoked potentials as a measure of demyelination. Evoked potentials are a possible way to measure repair by measuring the conduction speed of signals along axons | $49,948 | 2022 |
| Cornell UniversityIthaca, NY | MRF funds work at Cornell University to determine whether brain endothelial cell EVs, oligodendrocyte EVs and microglial EVs from MS patients' blood, changes with various MS sub-types | $26,000 | 2022 |
| Oregon Health & Science UniversityPortland, OR | Not available | $24,964 | 2021 |
| Nanosomix IncLaguna Niguel, CA | Nanosomix analyzed samples for MRF | $10,000 | 2023 |
| 1 |
| $0 |
| Eric Hsu | Director | 1 | $0 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Jun 30, 2024IRS bulk XML
Filing id 202433179349306093
Form 990 · FY2023 · period ending Jun 30, 2023
Filing id 202323179349309267
Form 990 · FY2022 · period ending Jun 30, 2022
Filing id 202203159349304385
Form 990 · FY2021 · period ending Jun 30, 2021
Filing id 202113169349306236
Form 990 · FY2019 · period ending Jun 30, 2019
Filing id 202011059349300901
Form 990 · FY2018 · period ending Jun 30, 2018
Filing id 201901309349301775
Form 990 · FY2017 · period ending Jun 30, 2017
Filing id 201811349349305996
Form 990 · FY2016 · period ending Jun 30, 2016
Filing id 201741329349306994
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.